For the second time in two months, Merck & Co. has unloaded an API plant in Europe. This time it is a plant in France that it has sold to Luxembourg-based contract manufacturer Fareva.
AMRI, the Albany, NY-based company that has been moving away from drug discovery toward manufacturing, said it's teaming with Saneca Pharmaceuticals of Slovakia to produce and sell a suite of opium-derived APIs.
Thailand-based pharma manufacturer Mega Lifesciences is partnering with Sydna Farma of Singapore as part of its efforts to expand into Indonesia.
Regis Technologies, a Morton Grove, IL-based CMO, has opened a new suite for manufacturing highly potent APIs.
The Indian Directorate of Revenue Intelligence arrested 6 people, including the owners of three pharmaceutical companies, for possession and distribution of pseudoephedrine.
Australia-based Mayne Pharma said it will spend $65 million to expand operations at its Greenville, NC, facility, including the construction of a 126,000-square-foot oral-dose facility.
It has been more than 6 years since Caraco Pharmaceutical Laboratories was forced to suddenly shut two Detroit-area manufacturing plants after the FDA sent in marshals to seize drugs, claiming the plants had contamination issues. One of the plants was even closed last year by Caraco owner Sun Pharmaceutical. But legal problems continue to reverberate for Sun for having laid off hundreds of workers without notice.
Sterigenics International, which counts vaccine and API sterilization among its irradiation services, is expanding.
The FDA publishes warning letters and inspection reports on its websites. It issues public recalls and drug label warnings. However, it is not feeling in such a sharing mood when it comes to its proposed letter grades for manufacturing plants on the quality of their manufacturing.
When Shire shelled out $4.2 billion for ViroPharma a couple of years ago, it picked up the rare disease drug Cinryze, but what it didn't get in the deal was complete control over manufacturing of the rare disease drug. That had been ceded by ViroPharma to Sanquin Blood Supply. But Shire has now worked a deal with Amsterdam-based Sanquin that will allow it to add more contract manufacturers and so boost production of the treatment.
Sucampo sees a number of advantages to buying Japanese CDMO R-Tech Ueno, not the least of which will be owning the manufacturing for the two drugs that it sells.
Novo Nordisk has had filling, packaging and prefilled device manufacturing in Clayton, NC for years. Now the Danish drugmaker is betting its manufacturing future on the site. It will spend $1.2 billion on its first-ever U.S. API plant there and double the site's employment by adding 700 jobs.
Animal health leader Zoetis has said that its massive cost-cutting plans will include whacking 10 unnamed manufacturing sites. But this week its manufacturing unit was taking solace in the expansion of one of its largest facilities.
With $97 million in angel investments and $14 million in milestone payments in hand, plus a pipeline of immuno-oncology drug candidates, China-based BeiGene believes it is time to look toward manufacturing.
Allergan Monday said it was going to pull some of its eye drugs from the market because of a problem with particles shedding from the tube cap which led to a "small number of customer complaints." The small number is nearly two dozen, including 12 consumers who said they had a foreign object in their eye as well as one report of swelling and another of blurred vision.
A South Carolina-based peptide maker intends to spend nearly $19 million to triple the size of its plant and headquarters and has promised the state it will add 100 jobs in the next 5 years.
Several years ago, GlaxoSmithKline sold off a portfolio of consumer products in the U.S. The drugmaker had indicated a plant in Memphis, TN, was going to be sacrificed as part of that decision but GSK still has the plant and is even planning to spend some money making improvements to it.
A new company financed by Bain Capital intends to stake a position in the sterile compounding market. QuVa Pharma has started by acquiring an FDA 503B registered compounding facility in Sugar Land, TX from Helix.
India's Aurobindo Pharma intends to beef up its manufacturing capacity over the next three years.
With its deal last year to combine consumer health operations with Novartis in a joint venture that GlaxoSmithKline will run, GSK CEO Andrew Witty bet a big piece of the drugmaker's future on products like OTC pain meds and toothpaste. While Witty has lauded the future of that operation, it has stumbled in that market with the recall of nearly 4 million tubes of toothpaste products that may give users splinters.